## UNITED STATES SECURITIES AND EXCHANGE COMMISSION October 3, 2014

## ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934

## Epirus Biopharmaceuticals, Inc.

File No. 0-51171 - CF#31473

Epirus Biopharmaceuticals, Inc. submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 10-Q filed on August 11, 2014.

Based on representations by Epirus Biopharmaceuticals, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

Exhibit 10.2	through August 11, 2017
Exhibit 10.3	through August 11, 2019
Exhibit 10.4	through August 11, 2017
Exhibit 10.5	through August 11, 2017
Exhibit 10.6	through August 11, 2019

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields Secretary